V.R. Archer

488 citations

14 papers · 354 indexed · h-index 8

Impact in

Oncology top 10%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in ⓘ

Pulmonary and Respiratory Medicine 12
- Lung Cancer Treatments and Mutations 10
- Lung Cancer Diagnosis and Treatment 5
- Gastric Cancer Management and Outcomes 3
Oncology 10
- Cancer Treatment and Pharmacology 4
- Lung Cancer Research Studies 4
- Colorectal Cancer Treatments and Studies 2

Co-authors: Petr Zatloukal (4 shared papers)Rodryg Ramlau (4 shared papers)Martin Reck (4 shared papers)Natasha B. Leighl (3 shared papers)J. Mezger (2 shared papers)Joachim von Pawel (3 shared papers)Victor J. Hirsch (1 shared paper)C. Manegold (1 shared paper)
Journals: Journal of Clinical Oncology (6 papers)Annals of Oncology (2 papers)Journal of Thoracic Oncology (1 paper)Lung Cancer (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
Partner nations: United Kingdom Switzerland South Korea

In The Last Decade

V.R. Archer

14 papers receiving 342 citations

Peers

Countries citing papers authored by V.R. Archer

Since Specialization

Citations

This map shows the geographic impact of V.R. Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.R. Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.R. Archer more than expected).

Fields of papers citing papers by V.R. Archer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.R. Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.R. Archer. The network helps show where V.R. Archer may publish in the future.

Co-authors

The 25 scholars most cited alongside V.R. Archer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with V.R. Archer Line = papers co-authored together V.R. Archer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 Journal of Clinical Oncology ·C. Manegold, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Victor J. Hirsch, Natasha B. Leighl, J. Mezger, V.R. Archer, Martin Reck	2007	128
2	Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens Lung Cancer ·Nicholas Thatcher, Amy Chang, Purvish Parikh, Kristine Pemberton, V.R. Archer	2005	53
3	Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival Journal of Clinical Oncology ·S. Jane Darnton, V.R. Archer, Deborah Stocken, Paul Mulholland, Alan G. Casson, D. Ferry	2003	41
4	Palliative Chemotherapy: No Longer a Contradiction in Terms The Oncologist ·V.R. Archer, Lucinda Billingham, M.H. Cullen	1999	35
5	Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) Journal of Clinical Oncology ·Vera Hirsh, Rodryg Ramlau, Joachim von Pawel, Petr Zatloukal, Gema Vera, Natasha B. Leighl, J. Mezger, V.R. Archer, Martin Reck	2009	26
6	Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Journal of Clinical Oncology ·Solange Peters, Tony Mok, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, Dong‐Wan Kim, M. Pérol, Sai‐Hong Ignatius Ou, Alice T. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, V.R. Archer, D. Ross Camidge	2020	19
7	Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL) Journal of Clinical Oncology ·N. B. Leighl, Petr Zatloukal, J. Mezger, Rodryg Ramlau, V.R. Archer, N. Moore, Martin Reck	2009	15
8	Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy Journal of Clinical Oncology ·V.R. Archer, Martin Reck, Alan B. Sandler, David H. Johnson, George Kong, Dudley K. Strickland, Jaafar Bennouna	2008	13
9	A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens Cancer Chemotherapy and Pharmacology ·Sarah Jordan, Christopher Poole, V.R. Archer, Neil Steven, Andrea Burton	2003	7
10	Combined Results from Three Phase II Trials of Neoadjuvant Chemotherapy in Operable Adenocarcinoma of the Oesophagus Clinical Oncology ·V.R. Archer, Paul Mulholland, Deborah Stocken, S. Jane Darnton, D. Ferry	2001	7
11	C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha B. Leighl, J. Mezger, V.R. Archer, Christian Manegold	2007	6
12	Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study JTO Clinical and Research Reports ·Caicun Zhou, You Lu, Sang‐We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, Se‐Hoon Lee, Jianhua Chang, Jian Fang, Zhe Liu, Lilian Bu, Qian Li, Tingting Xu, V.R. Archer, Magalie Hilton, Mingzhu Zhou, Li Zhang	2024	2
13	1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo) Annals of Oncology ·Benjamin Solomon, Yi‐Long Wu, Rafał Dziadziuszko, Fabrice Barlési, Makoto Nishio, J.S. Ahn, Hidehito Horinouchi, Maximilian J. Hochmair, Filippo de Marinis, M.R. Migliorino, A. Kurochkin, Hakan Harputluoğlu, D. Planchard, Krittiya Korphaisarn, J-Y. Han, T Lohmann, A. Cardona Gavaldon, V.R. Archer, Małgorzata Nowicka, Johannes Noé	2024	1
14	629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC) Annals of Oncology ·Chengcheng Zhou, Yidan Lu, S-W. Kim, T.R. Baisamut, Jianhui Zhou, Y. Zhang, J. He, J-J. Yang, Yufeng Cheng, SH Lee, J. Chang, J. Fang, Z. Liu, L. Bu, L. Qian, V.R. Archer, M. Zhou, L. Zhang	2024	1

About V.R. Archer

V.R. Archer is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Hepatology and Pathology and Forensic Medicine, having authored 14 papers that have together received 354 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers), Cancer Treatment and Pharmacology (4 papers), Lung Cancer Research Studies (4 papers), Gastric Cancer Management and Outcomes (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Esophageal Cancer Research and Treatment (2 papers). The work is most often cited by research in Oncology (249 citations), Pulmonary and Respiratory Medicine (274 citations), Hepatology (21 citations), Cancer Research (39 citations) and Surgery (55 citations). V.R. Archer has collaborated with scholars based in United Kingdom, Switzerland and South Korea. Frequent co-authors include Petr Zatloukal, Rodryg Ramlau, Martin Reck, Natasha B. Leighl, J. Mezger, Joachim von Pawel, Victor J. Hirsch, C. Manegold, Vera Gorbounova and Lucinda Billingham. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact